Molecularly targeted therapy in renal cell carcinoma: where do we go from here?

Abstract

The angiogenic phenotype of renal cell carcinoma results from vascular endothelial growth factor pathway activation. Several different strategies targeting various aspects of the pathway have emerged as clinically relevant therapeutics in metastatic renal cell carcinoma. Key clinical data regarding these approaches are presented in this article. Furthermore, there are several considerations as to the further development of these agents and their appropriate application in metastatic renal cell carcinoma, such as timing of therapy, choice of initial therapy, continued role of debulking nephrectomy and toxicity concerns. These issues are discussed in light of current data and strategies for further drug development are presented.

Keywords::

• bevacizumab
• CAIX
• COX-2
• cytokines
• renal carcinoma
• sorafenib
• sunitinib
• temsirolimus
• VEGF